India formulations and innovative medicines drive growth in Q1FY27, with management reiterating FY27 guidance. Margins face near-term pressure from investments and the Organon acquisition.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.